Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Requires review by Evolent for oncology medications and supportive agents for Medicare - Wellcare by Fidelis Care members prior to dispensing or administration across pharmacy, physician office, outpatient hospital, or ambulatory settings; applies to participating providers (non-participating submission instructions also provided).

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review prior to dispensing or administration (portal: my.newcenturyhealth.com or phone: 1-888-999-7713, option 1).
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+HCPCS/Codes listed that require review
    Medical & PharmacyBenefit types covered
    YesBiosimilar preferences provided
    3/1/2026Noted effective date for list

    Coverage Criteria & Scope

    Prior authorization / review criteria

    Covered when Evolent review is completed and medically accepted indication is established

    Evolent review requirement: Requests for listed oncology medications and supportive agents must be submitted to Evolent for review prior to dispensing or administration for participating providers.
    Submission requirement: The entire oncology regimen must be submitted to Evolent; omitting any part of the regimen may result in a denial.
    Settings covered: Pharmacy dispensing OR administration in physician office OR outpatient hospital OR ambulatory setting.

    Do NOT submit the following request types to Evolent for review: Antibiotics; Bone marrow, stem cell transplants, and CAR-T cell therapy; Controlled substances (e.g., morphine); Equipment requests (e.g., infusion pumps); Genetic laboratory testing and laboratory services; Hemophilia drugs; Inpatient drug requests; Inpatient radiation and chemotherapy treatments; Iron preparations; Radiopharmaceuticals; Surgeries/surgical procedures; Sickle cell diagnoses and therapies; Immune globulins.

    HCPCS / J-Codes and Effective Dates

    Sample listed HCPCS/J-codes (start of list)mixed
    C9293GLUCARPIDASE
    J0888(listed)
    C9307LINVOSELTAMAB-GCPT INJ
    Extensive HCPCS/J-code oncology drug listHCPCS
    J1442FILGRASTIM G-CSF 1 MCG INJ
    J2506PEGFILGRASTIM (ON-BODY INJECTOR) / PEGFILGRASTIM INJECTION
    J9035BEVACIZUMAB 10 MG
    J9312RITUXIMAB AND HYALURONIDASE HUMAN
    J9351TOPOTECAN INJ
    Q-codes / biosimilar identifiersHCPCS
    Q2043SIPULEUCEL-T AUTO CD5+
    Q5101FILGRASTIM-SNDZ
    Q5113TRASTUZUMAB-DTTB
    Pharmacy benefit / oral drug J-codes (pharmacy-only list)HCPCS
    J7520SIROLIMUS ORAL
    J8520CAPECITABINE ORAL
    J8999MULTIPLE ORAL ONCOLOGY AGENTS (listed individually in document)
    inv-07: Effective date for the coding list
    Effective date3/1/2026
    Applies toWellcare by Fidelis Care list
    ScopeEffective date applies to the oral J8999 oncology/ pharmacy benefit list shown in the document

    What Providers Must Do

    Prior Authorization

    Evolent review required

    Oncology medications and supportive agents require review by Evolent for all participating providers before dispensing or administration in any outpatient setting or physician office for members of all ages. Clinical trials may also be sent to Evolent for review. Submit requests via Evolent's web portal at my.newcenturyhealth.com or by phone at 1-888-999-7713, option 1. Non‑participating providers should submit requests to the plan via fax: 1-844-235-5090 (formerly 1-877-882-5892).

    • Evolent web portal: my.newcenturyhealth.com
    • Evolent phone: 1-888-999-7713, option 1
    • Non-participating provider fax (plan): 1-844-235-5090
    Note

    Biosimilar preference

    The plan has identified preferred biosimilar agents for certain oncology-related indications. Providers should consider these preferred agents when clinically appropriate, but still submit the selected agent to Evolent for review.

    • Erythropoiesis-stimulating agents — Medical benefit: Retacrit (if unavailable due to shortage: Epogen); Pharmacy benefit: Procrit

    Policy Background

    This policy provides an administrative prior authorization review process for oncology medications and supportive agents to confirm a medically accepted indication and appropriate benefit routing (medical vs. pharmacy). It applies to requests for listed oncology medications and supportive agents that must be submitted to Evolent for review prior to dispensing or administration across settings including pharmacy dispensing, physician office, outpatient hospital, and ambulatory sites. Providers must submit the entire oncology regimen to Evolent; omitting any part of the regimen may result in a denial.

    Out-of-Scope / Definitions

    inv-13: Out of scope with Evolent — request types not to submit
    Do NOT submit to EvolentAntibiotics; Bone marrow, stem cell transplants and CAR‑T; Controlled substances; Equipment requests; Genetic lab testing and laboratory services; Hemophilia drugs; Inpatient drug requests; Inpatient radiation and chemotherapy treatments; Iron preparations; Radiopharmaceuticals; Surgeries/surgical procedures; Sickle cell diagnoses and therapies; Immune globulins.
    Biosimilar agentsPreferred biosimilars (e.g., Retacrit, Trazimera, Mvasi, Zarxio) should still be sent to Evolent for review.
    Submission noteSubmit the entire oncology regimen to Evolent; omissions may result in a denial.

    Step Therapy / Preferred Agents

    Drug classPreferred agent(s)Provider requirement
    Erythropoiesis-stimulating agentsMedical benefit: Retacrit (if unavailable due to shortage: Epogen); Pharmacy benefit: ProcritPreferred agents should be used when appropriate but must still be submitted to Evolent for review prior to dispensing or administration
    Trastuzumab (HER2 agents)Medical benefit: Trazimera; Pharmacy benefit: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, TrazimeraPreferred agents should be used when appropriate but must still be submitted to Evolent for review prior to dispensing or administration
    Bevacizumab (VEGF inhibitors)Medical benefit: Mvasi, Zirabev; Pharmacy benefit: Avastin, Mvasi, ZirabevPreferred agents should be used when appropriate but must still be submitted to Evolent for review prior to dispensing or administration
    Hematopoietic agentsMedical & Pharmacy benefit: ZarxioPreferred agents should be used when appropriate but must still be submitted to Evolent for review prior to dispensing or administration

    Site of Care Requirements

    Prior Authorization

    Site-of-care review required (home, office, infusion center, hospital outpatient)

    Evolent review is required before dispensing or administration at the listed sites: home, physician office, infusion center, or hospital outpatient/ambulatory setting.

    • Requirement applies to dispensing at a pharmacy or administration in physician office, outpatient hospital, or ambulatory settings.

    Biosimilar Preferences

    Billing Rule

    Epogen / Procrit guidance — preferred ESA by benefit

    Preferred erythropoiesis-stimulating agents are specified by benefit: for the medical benefit Retacrit is preferred (if unavailable due to shortage use Epogen); for the pharmacy benefit Procrit is preferred.

    • Providers must still send selected agents to Evolent for review despite preference guidance.
    Billing Rule

    Trastuzumab biosimilar preferences and identifiers

    Preferred trastuzumab biosimilar for the medical benefit is Trazimera; multiple trastuzumab biosimilars (including Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, and Trazimera) are listed for the pharmacy benefit.

    • Even preferred trastuzumab products must be submitted to Evolent for review.
    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review prior to dispensing or administration (portal: my.newcenturyhealth.com or phone: 1-888-999-7713, option 1).
    SourceLink
    On This Page
    Coverage Criteria & ScopeHCPCS / J-Codes and Effective DatesWhat Providers Must DoPolicy BackgroundOut-of-Scope / DefinitionsStep Therapy / Preferred AgentsSite of Care RequirementsBiosimilar Preferences
  1. Trastuzumab — Medical benefit: Trazimera; Pharmacy benefit: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
  2. Bevacizumab — Medical benefit: Mvasi, Zirabev; Pharmacy benefit: Avastin, Mvasi, Zirabev
  3. Hematopoietic agents — Medical & Pharmacy benefit: Zarxio
  4. Documentation Required

    Submission channels

    Requests may be submitted through Evolent's web portal or by phone. Non‑participating providers must send requests to the plan via the designated fax number (see above). Ensure the correct submission channel is used to avoid delays.

    • Preferred submission: Evolent web portal (my.newcenturyhealth.com) or phone (1-888-999-7713, option 1)
    • Non-participating providers: submit to plan fax 1-844-235-5090
    Denial Risk

    Complete regimen submission required

    Submit the entire oncology regimen to Evolent for review, regardless of whether individual agents appear to require prior authorization. Omitting any part of the regimen may result in a denial.

    • Include all agents, supportive medications, and relevant procedural treatments that comprise the regimen
    • Do not split submissions — send the full regimen even if some drugs are covered without prior authorization